ASND logo

Ascendis Pharma A/S (ASND) EBITDA

Annual EBITDA

-$445.13 M
+$112.93 M+20.24%

December 31, 2023

Summary

Performance

1-Year Change

+20.24%

3-Year Change

+4.42%

5-Year Change

-191.14%

15-Year Change

-218.15%

ASND EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

2.25%
ASND annual EBITDA is higher than 2.25% of companies in Healthcare sector

High & Low

All-time High

$6.80 M
ASND annual EBITDA is currently -6648.79% below its historical high of $6.80 million

3-Year Low

-$558.07 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
ASND previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 7, 2025
ASND next annual earnings announcement is scheduled for Feb 7, 2025

OtherASNDprofitabilitymetrics:

Annual Revenue

$288.75 M
ASND annual revenue is $288.75 million

Annual Net Income

-$521.22 M
ASND annual net profit is -$521.22 million

Annual EBIT

-$465.61 M
ASND annual earnings before interest & taxes is -$465.61 million

Annual EPS

-$9.26
ASND annual earnings per share is -$9.26

Quarterly EBITDA

-$78.23 M
+$16.00 M+16.98%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+45.7%

3-Year Change

+12.33%

5-Year Change

-207.36%

ASND Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

4.32%
ASND quarterly EBITDA is higher than 4.32% of companies in Healthcare sector

High & Low

All-time High

$2.35 M
ASND quarterly EBITDA is currently -3427.45% below its historical high of $2.35 million

3-Year Low

-$196.46 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
ASND previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 7, 2025
ASND next earnings announcement is scheduled for Feb 7, 2025

OtherASNDprofitabilitymetrics:

Quarterly Revenue

$63.61 M
ASND quarterly revenue is $63.61 million

Quarterly Net Income

-$109.10 M
ASND quarterly net profit is -$109.10 million

Quarterly EBIT

-$80.10 M
ASND quarterly earnings before interest & taxes is -$80.10 million

Quarterly EPS

-$1.89
ASND quarterly earnings per share is -$1.89

TTM EBITDA

-$296.28 M
+$65.84 M+18.18%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+47.14%

3-Year Change

+41.98%

5-Year Change

-31%

ASND TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

4.58%
ASND TTM EBITDA is higher than 4.58% of companies in Healthcare sector

High & Low

All-time High

$2.35 M
ASND TTM EBITDA is currently <-9900.00% below its historical high of $2.35 million

3-Year Low

-$560.44 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
ASND previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 7, 2025
ASND next earnings announcement is scheduled for Feb 7, 2025

OtherASNDprofitabilitymetrics:

TTM Revenue

$354.82 M
ASND TTM revenue is $354.82 million

TTM Net Income

-$462.76 M
ASND TTM net profit is -$462.76 million

TTM EBIT

-$310.54 M
ASND TTM earnings before interest & taxes is -$310.54 million

TTM EPS

-$8.10
ASND TTM earnings per share is -$8.10

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$445.13 M
ASND annual EBITDA is -$445.13 million

Annual Net Income

-$521.22 M
ASND annual net profit is -$521.22 million

Annual Interest Expense

$47.71 M
ASND annual interest expense is $47.71 million

Annual Income Tax

$7.91 M
ASND annual income tax is $7.91 million

Annual D&A

$20.47 M
ASND annual depreciation & amortization is $20.47 million

ASND EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+20.2%+45.7%+47.1%
3 y3 years+4.4%+12.3%+42.0%
5 y5 years-191.1%-207.4%-31.0%

ASND EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-3.2%+20.2%-53.6%+60.2%at high+47.1%
5 y5-year-89.0%+20.2%-53.6%+62.4%-31.0%+47.1%
alltimeall time-6648.8%+20.2%-3427.4%+62.4%<-9999.0%+47.1%

Ascendis Pharma A/S EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$78.23 M(-17.0%)
-$296.28 M(-18.2%)
Jun 2024
-
-$94.23 M(+85.0%)
-$362.11 M(-6.1%)
Mar 2024
-
-$50.93 M(-30.1%)
-$385.53 M(-11.8%)
Dec 2023
-$445.13 M(-20.2%)
-$72.89 M(-49.4%)
-$436.88 M(-22.0%)
Sep 2023
-
-$144.06 M(+22.5%)
-$560.44 M(+3.7%)
Jun 2023
-
-$117.64 M(+15.0%)
-$540.65 M(+9.2%)
Mar 2023
-
-$102.28 M(-47.9%)
-$494.95 M(-5.2%)
Dec 2022
-$558.07 M(+29.4%)
-$196.46 M(+58.1%)
-$522.21 M(+18.5%)
Sep 2022
-
-$124.27 M(+72.7%)
-$440.78 M(+8.6%)
Jun 2022
-
-$71.94 M(-44.5%)
-$405.74 M(-14.9%)
Mar 2022
-
-$129.54 M(+12.6%)
-$476.83 M(+14.2%)
Dec 2021
-$431.44 M(-7.4%)
-$115.02 M(+28.9%)
-$417.66 M(-18.2%)
Sep 2021
-
-$89.23 M(-37.6%)
-$510.66 M(-0.7%)
Jun 2021
-
-$143.03 M(+103.2%)
-$514.42 M(+11.3%)
Mar 2021
-
-$70.37 M(-66.2%)
-$462.29 M(+0.7%)
Dec 2020
-$465.73 M(+97.8%)
-$208.02 M(+123.7%)
-$459.19 M(+36.0%)
Sep 2020
-
-$92.99 M(+2.3%)
-$337.56 M(+25.0%)
Jun 2020
-
-$90.91 M(+35.2%)
-$270.02 M(+15.3%)
Mar 2020
-
-$67.27 M(-22.1%)
-$234.12 M(+3.5%)
Dec 2019
-$235.48 M
-$86.39 M(+239.4%)
-$226.17 M(+28.5%)
Sep 2019
-
-$25.45 M(-53.7%)
-$176.00 M(-7.3%)
Jun 2019
-
-$55.01 M(-7.3%)
-$189.84 M(+17.3%)
DateAnnualQuarterlyTTM
Mar 2019
-
-$59.32 M(+63.8%)
-$161.89 M(+11.9%)
Dec 2018
-$152.90 M(+9.3%)
-$36.22 M(-7.8%)
-$144.68 M(-10.3%)
Sep 2018
-
-$39.29 M(+45.1%)
-$161.26 M(+1.7%)
Jun 2018
-
-$27.07 M(-35.7%)
-$158.55 M(+0.2%)
Mar 2018
-
-$42.11 M(-20.2%)
-$158.25 M(+12.3%)
Dec 2017
-$139.91 M(+85.8%)
-$52.79 M(+44.3%)
-$140.93 M(+29.3%)
Sep 2017
-
-$36.59 M(+36.7%)
-$109.02 M(+18.1%)
Jun 2017
-
-$26.77 M(+8.0%)
-$92.30 M(+14.8%)
Mar 2017
-
-$24.78 M(+18.7%)
-$80.42 M(+7.0%)
Dec 2016
-$75.32 M(+105.6%)
-$20.88 M(+5.2%)
-$75.18 M(+6.6%)
Sep 2016
-
-$19.86 M(+33.3%)
-$70.56 M(+20.6%)
Jun 2016
-
-$14.90 M(-23.7%)
-$58.53 M(+1.5%)
Mar 2016
-
-$19.54 M(+20.1%)
-$57.66 M(+58.8%)
Dec 2015
-$36.63 M(+180.5%)
-$16.26 M(+107.7%)
-$36.32 M(+33.3%)
Sep 2015
-
-$7.83 M(-44.2%)
-$27.25 M(+25.2%)
Jun 2015
-
-$14.03 M(-877.4%)
-$21.76 M(+109.1%)
Mar 2015
-
$1.81 M(-125.1%)
-$10.41 M(-17.9%)
Dec 2014
-$13.06 M(-292.1%)
-$7.19 M(+206.4%)
-$12.68 M(+303.4%)
Sep 2014
-
-$2.35 M(-12.4%)
-$3.14 M(+294.1%)
Jun 2014
-
-$2.68 M(+470.0%)
-$797.50 K(-142.4%)
Mar 2014
-
-$469.90 K(-120.0%)
$1.88 M(-20.0%)
Dec 2013
$6.80 M(+205.6%)
$2.35 M
$2.35 M
Dec 2012
$2.22 M
-
-

FAQ

  • What is Ascendis Pharma A/S annual EBITDA?
  • What is the all time high annual EBITDA for Ascendis Pharma A/S?
  • What is Ascendis Pharma A/S annual EBITDA year-on-year change?
  • What is Ascendis Pharma A/S quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Ascendis Pharma A/S?
  • What is Ascendis Pharma A/S quarterly EBITDA year-on-year change?
  • What is Ascendis Pharma A/S TTM EBITDA?
  • What is the all time high TTM EBITDA for Ascendis Pharma A/S?
  • What is Ascendis Pharma A/S TTM EBITDA year-on-year change?

What is Ascendis Pharma A/S annual EBITDA?

The current annual EBITDA of ASND is -$445.13 M

What is the all time high annual EBITDA for Ascendis Pharma A/S?

Ascendis Pharma A/S all-time high annual EBITDA is $6.80 M

What is Ascendis Pharma A/S annual EBITDA year-on-year change?

Over the past year, ASND annual EBITDA has changed by +$112.93 M (+20.24%)

What is Ascendis Pharma A/S quarterly EBITDA?

The current quarterly EBITDA of ASND is -$78.23 M

What is the all time high quarterly EBITDA for Ascendis Pharma A/S?

Ascendis Pharma A/S all-time high quarterly EBITDA is $2.35 M

What is Ascendis Pharma A/S quarterly EBITDA year-on-year change?

Over the past year, ASND quarterly EBITDA has changed by +$65.84 M (+45.70%)

What is Ascendis Pharma A/S TTM EBITDA?

The current TTM EBITDA of ASND is -$296.28 M

What is the all time high TTM EBITDA for Ascendis Pharma A/S?

Ascendis Pharma A/S all-time high TTM EBITDA is $2.35 M

What is Ascendis Pharma A/S TTM EBITDA year-on-year change?

Over the past year, ASND TTM EBITDA has changed by +$264.17 M (+47.14%)